ABIVAX Société Anonyme (AAVXF)
- Previous Close
5.81 - Open
5.81 - Bid 6.80 x 29200
- Ask 7.53 x 36100
- Day's Range
5.81 - 5.81 - 52 Week Range
5.81 - 15.15 - Volume
100 - Avg. Volume
9 - Market Cap (intraday)
438.435M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-3.19 - Earnings Date Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults and Phase 2b clinical trial of obefazimod in patients with Crohn's disease. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: AAVXF
View More
Performance Overview: AAVXF
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AAVXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AAVXF
View MoreValuation Measures
Market Cap
445.26M
Enterprise Value
392.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.62%
Return on Equity (ttm)
-148.98%
Revenue (ttm)
10.79M
Net Income Avi to Common (ttm)
-176.24M
Diluted EPS (ttm)
-3.19
Balance Sheet and Cash Flow
Total Cash (mrq)
144.36M
Total Debt/Equity (mrq)
269.12%
Levered Free Cash Flow (ttm)
-102.37M